MMSI MERIT MEDICAL SYSTEMS INC
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 856982 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY9.1%
TTM net income YoY35.2%
TTM EPS YoY36.9%
Revenue 3-yr CAGR9.5%
Net income 3-yr CAGR16.9%
Margins
Gross margin49.4%
Operating margin13.5%
Net margin9.9%
FCF margin12.6%
EBITDA margin21.3%
Returns
ROE9.8%
ROA5.8%
ROIC (approx.)8.5%
Asset turnover0.58x
Leverage & solvency
Liabilities / assets40.4%
Debt / equity0.42x
Current ratio4.52x
Interest coverage6.73x
Cash quality & payout
Operating cash flow / net income1.71x
Accruals ratio-4.1%
Payout ratio—
Capex / revenue4.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $416.24M | $418.84M | $381.88M | $393.94M | $384.16M | $382.46M | $355.35M | $355.16M |
| Cost of revenue | $215.61M | $203.68M | $197.08M | $198.58M | $197.75M | $197.97M | $183.33M | $182.18M |
| Gross profit | $200.63M | $215.17M | $184.80M | $195.35M | $186.41M | $184.49M | $172.02M | $172.98M |
| R&D expense | $22.39M | $25.39M | $22.61M | $26.54M | $23.97M | $24.37M | $22.48M | $25.19M |
| SG&A expense | $119.51M | $129.23M | $118.21M | $114.83M | $119.80M | $113.10M | $107.49M | $111.07M |
| Operating income | $58.76M | $60.40M | $44.16M | $54.20M | $42.61M | $46.88M | $41.03M | $36.56M |
| Interest expense | $7.33M | $12.12M | $6.53M | $6.36M | $6.75M | $6.78M | $6.57M | $7.99M |
| Pretax income | $55.78M | $51.31M | $53.55M | $51.06M | $38.54M | $43.38M | $37.96M | $33.15M |
| Income tax | $13.47M | $12.51M | $12.55M | $13.05M | $10.79M | $10.80M | $7.81M | $5.20M |
| Net income | $42.31M | $38.80M | $40.99M | $38.01M | $27.75M | $32.58M | $30.15M | $27.95M |
| EBITDA | $90.66M | $91.40M | $74.65M | $85.73M | $73.91M | $77.88M | $70.33M | $65.18M |
| EPS (basic) | 0.71 | 0.65 | 0.69 | — | 0.47 | 0.55 | 0.51 | — |
| EPS (diluted) | 0.70 | 0.65 | 0.68 | — | 0.46 | 0.54 | 0.49 | — |
| Weighted avg. shares (diluted) | 60.38M | 60.01M | 60.01M | — | 59.92M | 60.61M | 61.28M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $503.55M | $448.70M | $488.08M | $446.40M | $392.46M | $341.82M | $395.53M | $378.77M |
| Receivables | $221.87M | $224.24M | $206.45M | $203.71M | $210.29M | $204.16M | $199.55M | $190.24M |
| Inventory | $391.02M | $374.11M | $352.39M | $333.70M | $326.55M | $323.31M | $317.94M | $306.06M |
| Current assets | $1.20B | $1.11B | $1.10B | $1.04B | $985.53M | $923.07M | $958.63M | $923.77M |
| PP&E, net | $437.35M | $436.75M | $433.96M | $428.40M | $418.00M | $409.99M | $390.32M | $386.17M |
| Goodwill | $537.13M | $539.77M | $503.43M | $506.84M | $507.43M | $504.56M | $464.36M | $463.51M |
| Total assets | $2.92B | $2.86B | $2.72B | $2.69B | $2.63B | $2.59B | $2.47B | $2.42B |
| Current liabilities | $265.08M | $264.93M | $216.87M | $239.76M | $230.47M | $225.57M | $196.82M | $216.40M |
| Long-term debt | $737.40M | $736.26M | $735.16M | $734.04M | $732.92M | $731.79M | $730.67M | $729.55M |
| Total debt | $737.40M | $736.26M | $735.16M | $734.04M | $732.92M | $731.79M | $730.67M | $729.55M |
| Total liabilities | $1.18B | $1.18B | $1.09B | $1.10B | $1.10B | $1.10B | $1.04B | $1.04B |
| Shareholders' equity | $1.74B | $1.68B | $1.63B | $1.58B | $1.53B | $1.49B | $1.43B | $1.38B |
| Net debt | $233.85M | $287.56M | $247.08M | $287.63M | $340.46M | $389.98M | $335.14M | $350.78M |
| Shares outstanding | 59.90M | 59.71M | 59.66M | 59.42M | 59.29M | 59.22M | 59.08M | 58.74M |
| Cash flow statement | ||||||||
| Operating cash flow | $65.27M | $69.28M | $40.68M | $98.51M | $74.98M | $83.31M | $40.57M | $68.74M |
| Capital expenditure | $12.35M | $17.33M | $16.01M | $24.46M | $22.44M | $13.75M | $21.06M | $3.47M |
| Free cash flow | $52.93M | $51.95M | $24.67M | $74.05M | $52.54M | $69.56M | $19.51M | $65.27M |
| Investing cash flow | -$22.32M | -$110.13M | $7.73M | -$50.34M | -$24.07M | -$143.35M | -$29.64M | -$214.45M |
| Financing cash flow | $11.61M | $948,000 | -$6.29M | $5.06M | -$365,000 | $4.35M | $6.96M | $2.43M |
| Depreciation & amortization | $31.90M | $31.00M | $30.50M | $31.54M | $31.30M | $31.00M | $29.29M | $28.62M |
| Stock-based compensation | $13.62M | $12.91M | $8.96M | $9.90M | $13.61M | $10.87M | $9.08M | $9.52M |
Free plan shows the latest 8 periods; Pro shows all 67 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.